Singapore
Deep Intelligent Pharma (DIP), founded in 2017 and headquartered in Singapore, is poised to disrupt the pharmaceutical and biotech industries with its AI-native multi-agent platform technology. The company’s slogan, "Transforming pharmaceutical R&D through revolutionary AI-native multi-agent platform technology," highlights its commitment to innovation in clinical trials.
DIP leverages Generative AI to revolutionize the entirety of the clinical trial process, offering a solution that is faster, safer, and more cost-effective. Its platform allows for digital rehearsals of trials prior to commencement, covering everything from trial design and patient recruitment to analysis and regulatory reporting. This AI-driven, proactive approach positions DIP as a compelling candidate for investment in the evolving landscape of pharmaceutical research.
The absence of recent investment information suggests untapped potential, inviting venture capitalists and investors to explore opportunities with Deep Intelligent Pharma as they lead the charge in modernizing clinical trials.
